KEYMED BIO-B and Belenos enter into an exclusive licensing agreement for CM512 and CM536
I'm PortAI, I can summarize articles.
KEYMED BIO-B has entered into an exclusive licensing agreement with Belenos for CM512 and CM536. According to the agreement, Belenos will obtain the exclusive rights to CM512 and CM536 globally (excluding Greater China) and will pay KEYMED BIO-B a $15 million upfront payment and milestone payments. KEYMED BIO-B also has the opportunity to receive up to an additional $170 million. In addition, KEYMED BIO-B will receive tiered royalties on net sales. This agreement will strengthen KEYMED BIO-B's global collaboration network and enhance the value of its technology platform
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments